一种细菌金属β-内酰胺酶筛查方法的建立

目的　建立一种简便、易行的实验方法 ,检测细菌产生的金属酶。方法　根据协同试验原理 ,采用亚胺培南 (IP)与巯基乙酸 (MA)协同作用的方法检测金属酶 ,并与PCR方法检测金属酶基因进行比较。结果　 4 7株嗜麦芽窄食单胞菌全部产生了金属酶 ;14株黄杆菌中有 9株产生了酶 ;2 0株铜绿假单胞菌均没有产生金属酶。该检测结果与PCR法检测金属酶基因结果一致。结论　使用伊米配能与巯基乙酸协同作用的方法可以检测金属酶 ,该方法有较好的敏感性和特异性 ,并且操作简便 ,不需要特殊的仪器设备 ,适合用于临床微生物实验室筛查产金属酶的菌株。     

单侧唇腭裂的牙槽突裂植骨修复术

目的 :对唇腭裂中牙槽突裂患者应用牙槽突植骨术治疗后进行临床评价。方法 :利用髂骨松质骨移植于唇腭裂患者所形成的口鼻腔瘘之间。结果 :3年来临床应用该方法 ,治疗 2 3例牙槽突裂患者 ,其中 1 4例术后随诊 6个月以上 ,临床观察牙槽突裂已修复 ,X光显示骨密度同正常骨质。结论 :牙槽突植骨术是唇腭裂序列治疗的一个组成部分 ,为恢复上腭牙弓完整性。保证裂隙临近牙的萌出 ,提供稳固的上颌牙弓 ,增加鼻翼高度 ,改善鼻翼外形 ,均有重大的意义     

A型血与缺血性脑血管病

作者于1987年5月～1987年9月,通过对黑龙江省宁安县的三个乡32962人口的脑血管病流行病学调查,查出205例脑血管病患者,并为其中167例脑血管病患者做了血型测定(占81.4％)。发现A型血130例(占77.8％),其中脑血栓形成12。例(占61.1％),B型血34例(占20.3％),O型血3例(占1.8％)。A型血占多数,并与人群ABO血型分布构成比的差别有极显著差异,P值<0.001。故我们认为A型血可做为脑血管病的危险因素之一,并对A型血的人易患脑血管病,尤其缺血性脑血管病形成多的原因进行了探讨。     

银屑病分型论治浅解

银屑病又名牛皮癣,中医称之为白疕,是一种常见易复发的慢性炎症性皮肤病,以云母状鳞屑、红膜症、点状出血为临床特征.近年来,银屑病发病呈上升趋势,其初期有明显的季节性,呈冬重夏轻,无论男女老幼皆可发病,目前病因未明,尚缺乏有效的治疗方法.自2000年以来,我们根据银屑病的临床表现,将其辨证分型为:血热毒盛,寒湿侵袭、脉络瘀阻、血虚风燥、肝肾亏虚等五型,对证治疗取得了比较明显的疗效,现予介绍,以求同道斧正.     

补骨脂素混合结晶在S_(180)小鼠腹水和癌细胞内的浓度测定及药代动力学研究

补骨脂素混合结晶中补骨脂素在S_(180)小鼠腹水内属单室模型中呈双峰吸收。其动力学参数如下■l/2(h)为22.19;K_a(h~(-1))为12.3580;K(h-1)为0.0312;tlag(h)为0.0718;C_(max)(μg/ml)为6.3967;t_(max)(h)为0.5570;AUC(μg·h/ml)为175.0300。2亿S_(180)癌细胞内在0.25h时,其补骨脂素含量高达10.97μg/ml,腹水内补骨脂素含量既高且久,有利于肿瘤的冶疗。     

高频部分液体通气对吸入伤犬呼吸循环功能的影响

目的　观察高频部分液体通气 (highfrequencypartialliquidventilation ,HFPLV)对吸入性损伤犬肺力学、氧合和血流动力学参数的影响。　方法　 16条犬经吸入蒸气 ,造成重度吸入性损伤模型 ,并随机分为对照组和治疗组。两组动物致伤后均行高频喷射通气 (highfrequencyjetventila tiot,HFJV) ,治疗组同时经气管导管缓慢注入氟碳液体 (3ml/kg体重 ) ,行HFPLV治疗 ,于通气后3 0、60和 90min时测定两组动物血气、肺顺应性、气道阻力及血流动力学参数。　结果　治疗组PaO2 呈进行性上升 ,在各时相点与致伤后比较差异有显著性意义 (P <0 .0 5 ) ,而对照组各时相点与致伤后比较差异无显著性意义 (P >0 .0 5 ) ;治疗组PaCO2 也逐渐增高 ,于 60、90min显著高于致伤后水平 (P <0 .0 5 )。与对照组比较 ,治疗组各时相点的PaO2 稍有升高 (P >0 .0 5 ) ,PaCO2 于 90min显著增高 (P <0 .0 5 ) ,而两组动 /静态气道阻力、肺顺应性和血流动力学参数比较 ,差异均无显著性意义 (P >0 .0 5 )。　结论　HFPLV与单纯HFJV相比 ,更有利于吸入性损伤的动脉氧合 ,对血流动力学参数无明显不利影响     

A Randomized,Controlled Trial to Investigate the Effect of Ciclesonide and Beclomethasone Dipropionate on Eye Lens Opacity

Background. Inhaled corticosteroids (ICS) are recommended first-line therapy for the treatment of persistent asthma. However, reports from observational studies have suggested that the use of ICS may be associated with systemic adverse events, such as glaucoma and cataract (opacity of the lens) formation. Objective. To compare two ICS over 1 year regarding the formation/progression of lenticular opacities in patients with asthma. Methods. Adults (≥ 18 years of age) with moderate-to-severe asthma were randomized to ciclesonide 640 μ g/day (n = 785) or beclomethasone dipropionate 640 μ g/day (n = 783) in a multinational, double-blind, active-controlled, parallel-group study. The primary endpoint was the occurrence of a positive Class I grading shift (increase [worsening] in Lens Opacities Classification System [LOCS] III score of ≥ 0.5 for nuclear opalescence, ≥ 0.8 for cortical opacification, or ≥ 0.5 for posterior subcapsular opacification, or cataract surgery) in either eye at any visit over the 12-month, double-blind treatment period. Results. Mean changes (± standard error) in nuclear opalescence and cortical and posterior subcapsular opacification were small and similar between groups (ciclesonide 640 μ g/day: 0.10 ± 0.02, 0.07 ± 0.02 and 0.04 ± 0.01, respectively; beclomethasone dipropionate 640 μ g/day: 0.11 ± 0.02, 0.09 ± 0.02 and 0.03 ± 0.01, respectively). Class I shifts were observed in 34.3% versus 36.8% of ciclesonide-treated and beclomethasone dipropionate-treated patients, respectively. Ciclesonide 640 μ g/day was non-inferior to beclomethasone dipropionate 640 μ g/day regarding Class I shifts (risk ratio of ciclesonide to beclomethasone dipropionate, 0.940 [95% confidence interval, 0.820–1.077]); the 95% confidence interval upper bound was lower than the pre-specified non-inferiority bound of 1.333 (p < 0.0001), thereby excluding the possibility of higher risk ratio values. Conclusions. Mean changes in LOCS III scores were very small in both groups. Treatment with ciclesonide 640 μ g/day or beclomethasone dipropionate 640 μ g/day for 1 year has a minimal impact on lenticular opacities development and/or progression.